Ongoing Data Review for Vytorin, Zetia, and Zocor

Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)

This communication is based on information that FDA has not yet fully evaluated.

click anywhere outside the box to exit